Impact Biomedical
IBOImpact Biomedical Inc. (Stock Ticker: IBO) is a publicly traded life sciences company based in the United States. The company's primary business focus is the development and commercialization of technologies for the diagnosis and treatment of human diseases. Its operations are concentrated within the biotech and therapeutics sectors, with a specific emphasis on addressing cancer. The company's pipeline is built upon a portfolio of platform technologies. These include the Equivir and Equivir G platform for the treatment of viral infections and certain cancers, and the SnapCure platform designed for the discovery of therapeutic antibodies. Impact Biomedical's strategy involves advancing these platforms through internal research, strategic collaborations, and in-licensing agreements to develop product candidates. Impact Biomedical's key therapeutic areas of focus are oncology and virology. The company is working to translate its platform technologies into clinical applications, with research targeting specific cancers and infectious diseases. As a public entity, its progress is documented through its filings with the U.S. Securities and Exchange Commission.
IBO · Stock Price
Historical price data
About
Impact Biomedical Inc. (Stock Ticker: IBO) is a publicly traded life sciences company based in the United States. The company's primary business focus is the development and commercialization of technologies for the diagnosis and treatment of human diseases. Its operations are concentrated within the biotech and therapeutics sectors, with a specific emphasis on addressing cancer. The company's pipeline is built upon a portfolio of platform technologies. These include the Equivir and Equivir G platform for the treatment of viral infections and certain cancers, and the SnapCure platform designed for the discovery of therapeutic antibodies. Impact Biomedical's strategy involves advancing these platforms through internal research, strategic collaborations, and in-licensing agreements to develop product candidates. Impact Biomedical's key therapeutic areas of focus are oncology and virology. The company is working to translate its platform technologies into clinical applications, with research targeting specific cancers and infectious diseases. As a public entity, its progress is documented through its filings with the U.S. Securities and Exchange Commission.